Get started
Work

Abstract PS1-08-24: A phase 1/2 trial of LY4064809 (STX-478), a pan-mutant-selective PI3Kα inhibitor in HR+, HER2- advanced breast cancer (ABC): Updated results from PIKALO-1

Year: 2026
Type: conference-abstract
DOI: 10.1158/1557-3265.sabcs25-ps1-08-24
Authors: K. Jhaveri, D. Juric, A. Giordano, A. Italiano, G. Daniele, J. Rodon, A. Patnaik, J. Bartolomé, A. Elias, P. Munster, P. LoRusso, A. Soyano, M. de Miguel, J. O'Shaughnessy, R. Wesolowski, G. Curigliano, T. Hernández, A. Lombard, S. T. Estrem, L. Du, X. Xu, A. Montero
Institutions: Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, Dana-Farber Cancer Institute, Institut Bergonié, Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico, The University of Texas MD Anderson Cancer Center, South Texas Accelerated Research Therapeutics, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, University of Colorado Anschutz, University of California, San Francisco, Yale University, Moffitt Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, University of Milan, European Institute of Oncology, Delfos Hospital, Eli Lilly (United States), University Hospitals Seidman Cancer Center, Case Western Reserve University
Language: English
Field: Medicine
Open Access status: closed
OpenAlex ID: W7129272232
Cites:
Cited by:
Related to: